Market Research Logo

Global Heart Failure Drugs Market 2018-2022

Global Heart Failure Drugs Market 2018-2022

About Heart Failure Drugs

The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast period. Based on the drug class the market can be segmented into Beta blockers, ARBs, and ACE inhibitors. Angiotensin II receptor blockers (ARB) are a group of pharmaceuticals that modify the renin-angiotensin system. The heart disease drugs market is experiencing growth in the ARBs segment because it reduces the risk of death caused by heart failure and minimizes the chance of hospitalization of people with heart failure.

Technavio’s analysts forecast the global heart failure drugs market to grow at a CAGR of 10.46% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global heart failure drugs market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of heart failure drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Heart Failure Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Amgen
  • AstraZeneca
  • Bayer
  • Novartis


  • Other prominent vendors
  • Gilead
  • GlaxoSmithKline
  • Pfizer
  • Teva Pharmaceutical industries
Market driver
  • Rising geriatric population
  • For a full, detailed list, view our report
Market trend
  • Investment inclination toward developing countries
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Heart Failure Drugs Market 2018-2022

Technavio recognizes the following companies as the key players in the global heart failure drugs market: Amgen, AstraZeneca, Bayer, and Novartis.

Other Prominent Vendors in the market are: Gilead, GlaxoSmithKline, Pfizer, and Teva Pharmaceutical industries.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is investment inclination toward developing countries. Countries such as India, China; and Brazil are turning out to be some of the most attractive countries for pharmaceutical companies across the globe. Many factors such as huge share of global population and rising geriatric population are leading to the high growth of healthcare sector in the developing countries. In addition, the rising cases of lifestyle disorders such as obesity and diabetes also contribute to higher heart failure cases in the region.”

According to the report, one of the major drivers for this market is rising geriatric population. A large number of health problems are associated with the rising age, and CVDs are major among them. As a person gets older, the blood vessels become less flexible, thus making it difficult for the blood to flow through them. Rising age accompanied by other factors such as lifestyle-oriented diseases and smoking increases the risk of CVDs, especially heart failure. Heart failure in the geriatric population will continue to be a rising health burden globally, as this population represents the majority of the heart failure patients. Hence, rising geriatric population drives the demand for heart failure drugs during the forecast period.

Companies Mentioned

Amgen, AstraZeneca, Bayer, Novartis, Gilead, GlaxoSmithKline, Pfizer, and Teva Pharmaceutical industries.

  • Executive summary
  • Scope of the report
  • Research methodology
  • Introduction
    • Market outline
      • Table Heart function, before and after heart failure
      • Table Factors causing heart failure
      • Table Stages of heart failure
      • Table Major treatment options for various stages of heart failure
      • Table Global heart failure rate 2015
  • Market landscape
    • Market ecosystem
      • Table Parent market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition: Inclusions and exclusions checklist
    • Market sizing 2017
      • Table Market size 2017
      • Table Validation techniques employed for market sizing 2017
    • Market size and forecast 2017-2022
      • Table Global heart failure drugs market 2017-2022 ($ millions)
      • Table Global heart failure drugs market: Year-over-year growth 2018-2022 (%)
  • Five forces analysis
    • Table Five forces analysis 2017
    • Table Five forces analysis 2022
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Threat of new entrants
      • Table Threat of new entrants
    • Market condition
      • Table Market condition: Five forces 2017
  • Market segmentation by drug class
    • Segmentation by drug class
      • Table Global heart failure drugs market by drug class 2017-2022 (%)
    • Comparison by drug class
      • Table Comparison by drug class
    • Global beta blockers market
      • Table Global beta blockers market 2017-2022 ($ millions)
      • Table Common beta blockers used for CVDs
      • Table Global beta blockers market: Year-over-year growth 2018-2022 (%)
    • Global ARBs market
      • Table Global ARBs market 2017-2022 ($ millions)
      • Table Global ARBs market: Year-over-year growth 2018-2022 (%)
    • Global ACE inhibitors market
      • Table Global ACE inhibitors market 2017-2022 ($ millions)
      • Table Adverse effects of ACE inhibitors
      • Table Global ACE inhibitors market: Year-over-year growth 2018-2022 (%)
    • Global others market
      • Table Global others market 2017-2022 ($ millions)
      • Table Global others market: Year-over-year growth 2018-2022 (%)
    • Market opportunity by drug class
      • Table Market opportunity by drug class
  • Customer landscape
    • Table Customer landscape
  • Regional landscape
    • Geographical segmentation
      • Table Global heart failure drugs market by geography 2017-2022 (%)
    • Regional comparison
      • Table Regional comparison
    • Heart failure drugs market in Americas
      • Table Heart failure drugs market in Americas 2017-2022 ($ millions)
      • Table Heart failure drugs market in Americas: Year-over-year growth 2018-2022 (%)
    • Heart failure drugs market in EMEA
      • Table Heart failure drugs market in EMEA 2017-2022 ($ millions)
      • Table Heart failure drugs market in EMEA: Year-over-year growth 2018-2022 (%)
    • Heart failure drugs market in APAC
      • Table Heart failure drugs market in APAC 2017-2022 ($ millions)
      • Table Top Asian countries in terms of population with diabetes
      • Table Heart failure drugs market in APAC: Year-over-year growth 2018-2022 (%)
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table World population by age group 2015-2050 (millions)
      • Table Percentage of population aged 65 and above by region 2015 and 2050
      • Table Major complications of diabetes
      • Table Global obesity facts 2014
      • Table Percentage of workday spent walking or standing versus sitting in selected occupation 2016
    • Market challenges
      • Table Side effects of the drugs used in heart failure treatment and management
  • Market trends
    • Growing strategic alliances
    • Investment inclination toward developing countries
      • Table Demographic and economic snapshot of India and China
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
    • Competitive landscape
      • Table Competitive structure analysis of global heart failure drugs market
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • Amgen
      • Table Amgen: Vendor overview
      • Table Amgen: Business segments
      • Table Amgen: Organizational developments
      • Table Amgen: Geographic focus
      • Table Amgen: Segment focus
      • Table Amgen: Key offerings
    • AstraZeneca
      • Table AstraZeneca: Vendor overview
      • Table AstraZeneca: Business segments
      • Table AstraZeneca: Organizational developments
      • Table AstraZeneca: Geographic focus
      • Table AstraZeneca: Segment focus
      • Table AstraZeneca: Key offerings
    • Bayer
      • Table Bayer: Vendor overview
      • Table Bayer: Business segments
      • Table Bayer: Organizational developments
      • Table Bayer: Geographic focus
      • Table Bayer: Segment focus
      • Table Bayer: Key offerings
    • Novartis
      • Table Novartis: Vendor overview
      • Table Novartis: Business segments
      • Table Novartis: Organizational developments
      • Table Novartis: Geographic focus
      • Table Novartis: Segment focus
      • Table Novartis: Key offerings
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report